Has The Acquisition Of Cigna Corp. By Anthem, Inc. Been Relegated To The Dustbin Of History? Stay Tuned!

SM
Sheppard Mullin Richter & Hampton

Contributor

Sheppard Mullin is a full service Global 100 firm with over 1,000 attorneys in 16 offices located in the United States, Europe and Asia. Since 1927, companies have turned to Sheppard Mullin to handle corporate and technology matters, high stakes litigation and complex financial transactions. In the US, the firm’s clients include more than half of the Fortune 100.
On April 28, 2017, the U.S. Court of Appeals for the D.C. Circuit upheld a February 8, 2017 decision by the U.S. District Court for the District of Columbia to block the $54 billion acquisition...
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

On April 28, 2017, the U.S. Court of Appeals for the D.C. Circuit upheld a February 8, 2017 decision by the U.S. District Court for the District of Columbia to block the $54 billion acquisition of Cigna Corp. by Anthem, Inc.. U.S. et al. v. Anthem Inc. et al., case number 17-5024, U.S. Court of Appeals for the District of Columbia Circuit.

In its 2-1 decision, the Court of Appeals concluded that the District Court was correct to halt the deal, "based on Anthem's failure to show the kind of extraordinary efficiencies necessary to offset the conceded anticompetitive effect of the merger" in 14 states – such effects including "the loss of Cigna, an innovative competitor in a highly concentrated market." In his dissent, Judge Brett Kavanaugh argued that the Anthem/Cigna combination would benefit the biggest customers, mainly large companies with employees in many states.   In addition, Judge Kavanaugh argued that although the combined companies would require higher payments to manage its accounts, the effect would be offset by the combination's ability to negotiate lower rates from its providers.

Now that the Court of Appeals has likely doomed Anthem's attempted acquisition of Cigna, it may be a good time to consider the larger implications and meaning of the demise of the Anthem/Cigna deal, and, lest we forget, the Aetna/Humana deal, another health insurance combination that was called off as a result of a January 23, 2017 D.C. District Court decision holding that, "the merger of Aetna and Humana would be likely to substantially lessen competition in markets for individual Medicare Advantage plans and health insurance sold on the public exchanges" in 364 counties. Sound familiar?

In the coming days, the Sheppard Mullin Healthcare Blog will include further discussion and analysis of the Anthem/Cigna decision and what it may portend for healthcare merger/ acquisition efforts in the future.  What is to be learned from the shared fates of Anthem/Cigna and Aetna/Humana? Are powerhouse healthcare insurance deals going to give way to smaller healthcare insurance combinations in the future? Have the Anthem/Cigna and Aetna/Humana decisions shed any light on the antitrust analysis that will be applied to future combinations in the healthcare space? How does the fate of the ACA impact the healthcare antitrust opinions of tomorrow?

All of the above and more will be the focus of blog articles to be posted on this blog in the coming days.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More